Inherent Biosciences Raises Series A Funding Led By Propel Bio Partners To Redefine The Path To Parenthood By Elevating The Standard Of Care In Male Reproductive Health

Sep 07, 2022•about 3 years ago

Round Type

series a

Salt Lake CityBiotechnologyHealth CareGeneticsTherapeutics

Description

Inherent Biosciences, the first Utah company involved in commercializing a diagnostic in the emerging biotech field of epigenetics, has raised Series A funding from an investor group led by Los Angeles-based Propel Bio Partners toward Inherent's goal of changing the course of reproductive health.

Company Information

Company

Inherent Biosciences

Location

Salt Lake City, Utah, United States

About

Inherent Biosciences is pioneering epigenetic medicine for complex diseases. Gene dysregulation, a hallmark of complex disease, has been difficult to detect and treat, until now... Our epigenetic platform detects dysregulation across multiple genes and related pathways. We're pioneering a new category of diagnostics and therapeutics that leverage epigenetics, biology's inherent mechanism for gene regulation, to radically transform how we diagnose and treat complex diseases like infertility, autoimmune disease, autism, and other complex diseases. Our first products help patients suffering from infertility.

Inherent Biosciences Raises Series A Funding Led By Propel Bio Partners To Redefine The Path To Parenthood By Elevating The Standard Of Care In Male Reproductive Health

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information